SecProbe.io

CORRESP
1
filename1.htm

      RedHill Biopharma Ltd.

      21 Ha'arba'a Street

      Tel Aviv, 6473921, Israel

      February 15, 2024

      VIA EDGAR

      United States Securities and Exchange Commission

        Division of Corporation Finance

      Office of Life Sciences

      100 F Street N.E.

        Washington, D.C. 20549

      Attention: Tim Buchmiller

            Re:

              RedHill Biopharma Ltd.

                Registration Statement on Form F-1

                Filed February 9, 2024

                File No. 333-276979 (the “Registration Statement”)

      Ladies and Gentlemen:

      Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on February 15, 2024, or as soon thereafter
        as practicable.

      The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by
        calling Alla Digilova at (212) 659-4993, and that such effectiveness also be confirmed in writing.

                Very truly yours,

                REDHILL BIOPHARMA LTD.

                By:

                /s/ Dror Ben-Asher

                  Dror Ben-Asher

                    Chief Executive Officer and Chairman of the Board of Directors

              cc:

              Rick A. Werner, Esq., Haynes and Boone, LLP

              Alla Digilova, Esq., Haynes and Boone, LLP